佰仁医疗: 佰仁医疗控股股东和实际控制人行为规则(2025年8月)

Core Points - The document outlines the rules governing the behavior of the controlling shareholders and actual controllers of Beijing Bairen Medical Technology Co., Ltd, aiming to enhance corporate governance and ensure the company's healthy development [1][2][3] Group 1: General Principles - The rules are established to improve the corporate governance structure of the company and ensure its normal operation [1] - Controlling shareholders and actual controllers must comply with laws and regulations, exercising their rights without harming the interests of the company and other shareholders [2] - They are required to act in good faith, maintain the company's quality, and uphold the common interests of all shareholders [3] Group 2: Corporate Governance - Controlling shareholders and actual controllers must establish systems to clarify decision-making processes for significant matters and ensure the company's independence [5] - They should protect the integrity of the company's assets and not infringe upon the company's rights to its property [6] - They are prohibited from influencing the company's personnel independence and financial independence through improper means [9][10] Group 3: Information Disclosure - Controlling shareholders and actual controllers must fulfill their information disclosure obligations, ensuring that disclosed information is truthful, accurate, complete, and timely [6][7] - They must notify the company of significant events that could impact the company's securities trading prices [7][8] - They are required to maintain confidentiality regarding undisclosed significant information and not use it for personal gain [11][12] Group 4: Share Trading and Control Transfer - Controlling shareholders and actual controllers must adhere to legal regulations when trading company shares and must report any changes in shareholding that exceed specified thresholds [38][39] - They are prohibited from increasing their shareholding under certain conditions, such as during specific reporting periods [41] - Any transfer of control must be conducted fairly and without harming the interests of the company and other shareholders [42][43]